In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using $^{68}$Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages

Zohreh Varasteh1,2*, Miriam Braeuer1, Sarajo Mohanta3, Anna-Lena Steinsiek4, Andreas Habenicht3, Negar Omidvari1, Geoffrey J. Topping1, Christoph Rischpler2, Wolfgang A. Weber1, Hendrik B. Sager4, Geert Raes6,7, Sophie Hernot8 and Markus Schwaiger1

1 Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, 2 Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, 3 Institute for Cardiovascular Prevention, University Hospital of Ludwig-Maximilians-University, Munich, Germany, 4 Department of Cardiology, German Heart Centre Munich, Technical of University Munich, Munich, Germany, 5 DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany, 6 Laboratory of Cellular and Molecular Immunology (CMIM), Vrije Universiteit Brussel, Brussels, Belgium, 7 Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium, 8 Laboratory for in vivo Cellular and Molecular Imaging, ICMI-BEFY/MIMA, Vrije Universiteit Brussel, Brussels, Belgium

Introduction and Objectives: Wound healing after myocardial infarction (MI) is a dynamic and complex multiple phase process, and a coordinated cellular response is required for proper scar formation. The current paradigm suggests that pro-inflammatory monocytes infiltrate the MI zone during the initial pro-inflammatory phase and differentiate into inflammatory macrophages, and then switch their phenotypes to anti-inflammatory during the reparative phase. Visualization of the reparative phase post-MI is of great interest because it may reveal delayed resolution of inflammation, which in turn predicts adverse cardiac remodeling. Imaging of anti-inflammatory macrophages may also be used to assess therapy approaches aiming to modulate the inflammatory response in order to limit MI size. Reparative macrophages can be distinguished from inflammatory macrophages by the surface marker mannose receptor (MR, CD206). In this study we evaluated the feasibility of $^{68}$Ga-NOTA-anti-MMR Nb for imaging of MR on alternatively activated macrophages in murine MI models.

Methods: Wildtype and MR-knockout mice and Wistar rats were subjected to MI via permanent ligation of the left coronary artery. Non-operated or sham-operated animals were used as controls. MR expression kinetics on cardiac macrophages was measured in mice using flow cytometry. PET/CT scans were performed 1 h after intravenous injection of $^{68}$Ga-NOTA-anti-MMR Nb. Mice and rats were euthanized and hearts harvested for ex vivo PET/MRI, autoradiography, and staining. As a non-targeting negative control, $^{68}$Ga-NOTA-BCII10 was used.
INTRODUCTION

Acute myocardial infarction (MI) and heart failure (HF) are highly prevalent causes of morbidity and mortality in western societies (1–3). Post-MI inflammation plays a critical role in ventricular remodeling and development of congestive HF (4).

After MI, cardiomyocyte necrosis activates the innate immune system and triggers a cascade of inflammatory pathways (5). Macrophage infiltration in the infarct is a prominent sign of inflammation after MI, which has become a subject of interest in the process of post-infarction cardiac remodeling (6). Macrophages have been reported to have a double-edged-sword effect, including both detrimental and reparative functions in MI injury and post-infarction cardiac healing (7). On one hand, dysregulated and excessive recruitment of the inflammatory monocytes/macrophages into the infarct myocardium are harmful, resulting in tissue destruction and finally adverse cardiac remodeling. On the other hand, a controlled infiltration of monocytes/macrophages is integral to tissue repair and to wound healing resulting in stable scar (7). These diverse functions have been attributed to the distinct macrophage phenotypes: classically activated (pro-inflammatory, M1) and alternatively differentiated (anti-inflammatory, M2) subsets. Therefore, a promising therapeutic strategy for post-MI wound healing may be the suppression of adverse effects of pro-inflammatory macrophages, while sparing the favorable roles of the reparative macrophages to optimize tissue repair. Later, the biphasic recruitment of monocytes/macrophages into the ischemic myocardial injury provided a possible solution and a path to enhance the healing process (8, 9).

After MI, monocytes are recruited into the infarct zone in two distinct but overlapping phases (Figure 1) (8, 9). In the early inflammatory phase (phase I), the sterile wound recruits inflammatory monocytes from the blood, which differentiate into inflammatory macrophages that eliminate damaged cells and matrices. In the following reparative phase (phase II), recruited monocytes and macrophages functionally shift from promoting inflammation to resolving inflammation. Impaired resolution of inflammation may result in prolonged inflammatory phase I, adverse cardiac remodeling and consequently heart failure (8, 9). Therefore, it is of particular interest to follow the course of the inflammatory process after MI and to monitor the time-dependent presence of the different macrophage phenotypes in the infarcted myocardium in order to predict cardiac wound healing and hence the fate of the patients for years to come. Molecular imaging techniques that can detect the molecular signatures of different macrophage subsets may provide highly specific assessment of cardiac wound healing.

The main characteristics of distinct macrophages present in each phase are related to different surface expression markers. A portion of M2-oriented macrophages express carbohydrate-binding receptors, e.g., mannose receptor (MR, CD206), which is a 175 kDa highly effective endocytic C-type lectin receptor (10).

Nanobodies (Nbs) against macrophage mannose receptor (MMR) have been developed, and their potential as in vivo diagnostic tracers for non-invasive imaging of a subpopulation of tumor-infiltrating macrophages (11, 12) and joint inflammation in rheumatoid arthritis (13) are well documented. In the previous study, we were able to visualize the presence of MR-positive (MR+) macrophages in atherosclerotic plaques using a gallium-68 (68Ga)-labeled NOTA-coupled anti-MMR Nb (68Ga-NOTA-anti-MMR Nb) in a mouse model (14). In the present study, we sought to image cardiac MR+ M2 macrophages, using the same tracer. For this aim, NOTA-anti-MMR Nb was labeled with 68Ga and thoroughly assessed as a tracer for non-invasive in vivo nuclear molecular imaging of MR+ macrophages after MI using mouse and rat infarction models.

RESULTS

In vivo-PET/CT scans showed focal radioactivity signals in the infarcted myocardium for 68Ga-NOTA-anti-MMR Nb which were confirmed by ex vivo-PET/MRI scans. In autoradiography images, augmented uptake of the tracer was observed in infarcts, as verified by the histochemistry analysis. Immunofluorescence staining demonstrated the presence and co-localization of CD206- and CD68-positive cells, in accordance to infarct zone. No in vivo or ex vivo signal was observed in the animals injected with control Nb or in the sham-operated animals. 68Ga-NOTA-anti-MMR Nb uptake in the infarcts of MR-knockout mice was negligibly low, confirming the specificity of 68Ga-NOTA-anti-MMR Nb to MR.

CONCLUSION

This exploratory study highlights the potential of 68Ga-NOTA-anti-MMR Nb to image MR-positive macrophages that are known to play a pivotal role in wound healing that follows acute MI.

Keywords: myocardial infarction, inflammation, M2 macrophages, reparative phase, PET

MATERIALS AND METHODS

Mouse and Rat Models of Myocardial Infarction

A total of 30 C57BL/6 mice (female, 5-7-week-old, 18-21 g weight, from Charles River Laboratories), 12 C57BL/6 MR-deficient mice (mixed gender, in-house breeding, Vrije Universiteit Brussel),
and 15 Wistar rats (male, 3-month-old, 360-395 g weight, from Charles River Laboratories) were used for this study. A group of animals were subjected to MI by permanent ligation of the left anterior descending (LAD) coronary artery as described earlier (15). Briefly, before initiation of the operation, anesthesia was induced by intramuscular administration of 0.5 mg/kg medetomidine (Pfizer, Germany), 5 mg/kg midazolam (Roche, Germany) and 0.05 mg/kg fentanyl (Ratiopharm, Germany). Animals were ventilated artificially throughout the whole procedure using rodent ventilators. After performing a left-sided thoracotomy, the left ventricle was visualized and the left coronary artery was permanently ligated. Successful coronary occlusion was verified visually by identification of cyanosis/paling of the myocardium downstream of the suture. Subsequently, the chests were closed and animals received appropriate pain medication for 1 week following the operation. Non-operated or sham-operated (underwent the same surgical procedure except the ligation) animals were used as controls. Sham-operated animals underwent the same surgical procedure except the ligation.

**Flow Cytometry**

Mannose receptor expression kinetic on cardiac macrophages was measured in mice using flow cytometry as described earlier (16). In brief, mice were sacrificed on days 2, 7, and 14 post-MI (n = 5-7 mice per time point), hearts were extensively flushed with PBS and then removed. Working myocardium was separated using a dissection microscope, minced with scissors and digested in collagenase I (450 U/ml), collagenase XI (125 U/ml), DNase I (60 U/ml) and hyaluronidase (60 U/ml) (Sigma-Aldrich, St. Louis, MO, United States) at 37°C at 750 rpm for 1 h. Hearts were then homogenized through a 40-µm cell strainer. Total viable cell numbers were obtained using Trypan blue (Cellgro, Mediatech, Inc., VA, United States). For myeloid cell staining, cell suspensions were stained with mouse hematopoietic lineage markers (lineage for myeloid staining) including phycoerythrin (PE) anti-mouse antibodies directed against B220 (clone RA3-6B2, BD Bioscience), CD90 (clone 53-2.1, BD Bioscience), CD49b (clone DX5, BD Bioscience), NK1.1 (clone PK136, BD Bioscience), Ly6G (clone 1A8, BD Bioscience) and Ter-119 (clone TER-119, BD Bioscience). We then applied a second round of staining covering CD45.2 (clone 104, BD Bioscience), CD11b (clone M1/70, BD Bioscience), CD115 (clone M1/70, eBioscience), CD11c (clone HL3, eBioscience), F4/80 (clone BM8, Biolegend), CD206 (clone C068C2, Biolegend), and Ly6C (clone AL-21, BD Bioscience). Macrophages were identified as (B220/CD90/CD49b/NK1.1/Ly6G/Ter119) low (CD45.2/CD11b) high Ly6C low/int F4/80 high. We acquired data on an LSR Fortessa flow cytometer (BD Bioscience) with FACSDiva software (BD Bioscience). Experimental data were later analyzed using Flowjo software (Tree Star Inc.). Non-operated steady state mice were used as controls.

**Radiolabeling and Purification**

Both targeting (NOTA-anti-MMR Nb) and non-targeting (NOTA-BCII10 Nb) nanobodies were labeled with 68Ga at room temperature following the protocol described earlier (14). Briefly, 25 µl (~ 55 µg) of Nb solutions was incubated with 2.250-2.275 ml (~ 400 MBq) of gallium eluate (in 0.05 M HCl) and 200 µl of sodium acetate buffer (2 M, pH 5) for 15 min. Radiochemical purity (RCP) of the tracers were determined by radio-instant thin layer chromatography (radio-ITLC). For further animal studies the radiotracers were purified using a PD-10 column (GE Healthcare). Briefly, the reaction mixtures were passed through the column, preconditioned with 25 ml of PBS. The radiolabeled products were eluted with 8 × 500 µl fractions of PBS.

**In vivo PET/CT and ex vivo PET/MRI**

In vivo images acquired 1 h after intravenous injection of 68Ga-NOTA-anti-MMR Nb or 68Ga-NOTA-BCII10 Nb. At preselected time points (2, 7, and 14 days after MI), MI-induced C57BL/6 mice (n = 6) were scanned using an Inveon small animal PET/CT scanner (Siemens, Knoxville, TN, United States) after i.v. injection of 68Ga-NOTA-anti-MMR Nb (8–10 MBq, 3–4 µg). Consecutive 18FDG PET/CT acquisitions were also performed.
in mice, 7 days post-MI. MI-induced rats \((n = 7)\) were scanned 7 days post-MI after i.v. injection of \(^{68}\text{Ga}\)-NOTA-anti-MMR Nb \((20–25 \text{ MBq}, 8–10 \mu\text{g})\). MI rats \((n = 4)\) injected with non-targeting nanobody \(^{68}\text{Ga}\)-NOTA-BCII10 Nb \((20–23 \text{ MBq}, 8–10 \mu\text{g})\), and sham-operated rats \((n = 3)\) injected with \(^{68}\text{Ga}\)-NOTA-anti-MMR Nb were used as controls. Animals were kept fully sedated with 1.5–2% isoflurane throughout injections and PET/CT imaging. Breathing was monitored and temperature was maintained using a heating pad during the imaging procedures. PET and CT images were co-registered for anatomical reference. ROIs were drawn around the focal injection sites in mice \((n = 2)\) and MI rats \((n = 2)\) were also scanned \textit{ex vivo}. Briefly, after the completion of the \textit{in vivo} experiment, animals were sacrificed by a high dose of Pentobarbital \((\text{Narcoren})\), 7 days post-MI. After thoracotomy, the hearts were excised and rinsed with saline solution and scanned \textit{ex vivo} using a small animal PET insert \((\text{MADPET4, Klinikum rechts der Isar, Germany})\) in a preclinical 7 T MRI scanner \((\text{Agilent/GE MR901 magnet with Bruker AVANCE III HD electronics})\) for anatomical reference using a 3D T1-weighted spoiled gradient-recalled echo pulse sequence, as described earlier \((15)\). In order to keep the left ventricles open, rat hearts were filled with saline to confirm the origin of the \textit{in vivo} signal, hearts from MI mice \((n = 2)\) and MI rats \((n = 2)\) were also scanned \textit{ex vivo}. The mean radioactivity concentrations within the ROIs were expressed as kilobecquerel per milliliter \((\text{kBq/ml})\). In order to validate the results obtained by \textit{in vivo} PET/CT imaging and to confirm the origin of the \textit{in vivo} signal, hearts from MI mice \((n = 2)\) and MI rats \((n = 2)\) were also scanned \textit{ex vivo}. 

**Ex vivo Evaluation of the Tracer Biodistribution**

The \textit{ex vivo} spatial distribution of radioactivity in the heart sections was examined using autoradiography. Excised hearts from wildtype \((n = 4 \text{ MI and } n = 2 \text{ sham})\) and MR-knockout \((n = 4 \text{ MI and } n = 3 \text{ sham})\) mice as well as sham-operated \((n = 2)\) and MI-induced \((n = 4 \text{ injected with targeting Nb and } n = 4 \text{ injected with non-targeting Nb})\) rats were embedded in Tissue-Tek mounting media \((\text{Sakura Finetek})\) and frozen on dry ice. Serial short-axis cryosections of 10 \(\mu\text{m}\) thickness were obtained. Consecutive sections were used alternately for autoradiography and hematoxylin and eosin \((\text{H.E.})\) staining. After quick air drying, the tissue slices were covered with a layer of plastic wrap and exposed to the phosphor imaging plates \((\text{Fuji Imaging Plate, FUJIFILM})\). After an overnight exposure, the imaging plates were scanned with a phosphor imaging system \((\text{Raytest, Straubenhardt, Germany})\) in a preclinical 7 T MRI scanner \((\text{Agilent/GE MR901 magnet with Bruker AVANCE III HD electronics})\) for anatomical reference using a 3D T1-weighted spoiled gradient-recalled echo pulse sequence, as described earlier \((15)\). In order to keep the left ventricles open, rat hearts were filled with saline to confirm the origin of the \textit{in vivo} signal, hearts from MI mice \((n = 2)\) and MI rats \((n = 2)\) were also scanned \textit{ex vivo}. 

**Immunofluorescence Staining and Confocal Microscopy**

For immunofluorescence staining, rat heart specimens were embedded in Tissue Tek medium, frozen on dry ice, and stored at \(-80^\circ\text{C}\). 10-\(\mu\text{m}\)-thick cryosections were prepared and parallel sections were immunostained. Briefly, slides were thawed at room temperature and fixed with acetone, rehydrated in phosphate buffer saline, blocked with 10% donkey serum, and incubated 3 h with primary antibodies diluted with 2.5% bovine serum albumin \((\text{BSA})\). Primary antibodies include mouse anti-rat CD68 \((\text{clone ED}-1, \text{Bio-Rad})\) for macrophages and rabbit anti-MR antibody \((\text{polyclon, Abcam})\) for MR. Corresponding secondary antibodies were conjugated with Alexa 488 and Cy5. DAPI was used for DNA staining. For negative controls, staining was performed without primary antibodies. Stained sections were analyzed using a DM6000 fluorescence microscope and a SP8 confocal laser scanning microscope \((\text{Leica, Mannheim, Germany})\). Fluorophores were visualized by using a 488 nm excitation filter and 505/530 nm emission filter for Alexa 488, and a 633 nm excitation, and 650 nm emission long-pass filter for Cy5. For 3D imaging, z-stacks were prepared at 1 \(\mu\text{m}\) intervals with a scan zoom factor 2 using 100× objective and then processed LasX software \((\text{Leica})\).

**Statistics**

Data are expressed as mean \(\pm\) SD. The Mann–Whitney \(U\) test was used to compare two variables and 1-way ANOVA was used to compare multiple variables. A \(P\) value of 0.05 or less was considered to be significant. Statistical analysis was performed using SPSS Statistics software \((\text{version 24.0.0; IBM})\).

**RESULTS**

**MR\(^+\) Macrophages Accumulate in the Injured Myocardium With a Flow Cytometry-Based Peak at 7 Days Post-myocardial Infarction**

The total number of macrophages \((\text{Figure 2A})\) as well as MR\(^+\) macrophages \((\text{Figure 2B})\) were enumerated from working myocardium at different time points after MI using flow cytometry. Macrophages accumulated in the infarcted heart as early as 2 days after MI \([31.6 \pm 11.7 \times 10^3 \text{ MACS/mg}]\) and peaked on day 7 after MI \([57.7 \pm 14.3 \times 10^3 \text{ MACS/mg}]\). The number of MR\(^+\) macrophages rose during the reparative phase \([31.6 \pm 11.7 \times 10^3 \text{ MR}^+ \text{ MACS/mg}]\) and dropped on day 14 after MI \([2.6 \pm 1.7 \times 10^3 \text{ MR}^+ \text{ MACS/mg}]\), reaching levels similar to steady state \([0.6 \pm 0.3 \times 10^3 \text{ MR}^+ \text{ MACS/mg}]\) and day 2 after MI \([1.4 \pm 0.6 \times 10^3 \text{ MR}^+ \text{ MACS/mg}]\). The lowest MR expression level was observed in macrophages isolated from hearts 2 days post-MI \([2,563 \pm 379 \text{ mean fluorescent intensity (MFI) } \pm \text{ SD}]\). Macrophages from day 7 and 14 after MI showed protein levels of MR comparable to counterparts from
FIGURE 2 | Flow cytometric quantification of (A) total number of macrophages, (B) MR⁺ macrophages, and (C) MR expression level on cardiac macrophages in non-infarcted (steady state) and infarcted (2, 7, and 14 days after coronary ligation) wildtype mice hearts. Data are derived from \( n = 5-7 \) mice per time point.

\* \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \).

FIGURE 3 | Representative in vivo imaging of \(^{68}\)Ga-NOTA-anti-MMR Nb uptake in a longitudinal study. (A) Static PET/CT matched axial, coronal and sagittal slices in the same mouse subjected to coronary ligation and scanned 1 h after injection of \(^{68}\)Ga-NOTA-anti-MMR Nb (2, 7, and 14 days after MI). In order to validate the results obtained by in vivo PET/CT imaging (in \( n = 6 \) mice) and to confirm the cardiac origin of the in vivo signal, hearts from two MI-induced mice were also scanned ex vivo. (B) MR only and (C) PET/MRI of the heart excised from a mouse, 7 days after coronary ligation, confirming augmented \(^{68}\)Ga-NOTA-anti-MMR Nb uptake in the area close to the ligation site.

steady state (5,414 ± 427, 5,240 ± 817, and 5,405 ± 631 MFI, respectively) (Figure 2C).

\(^{68}\)Ga-NOTA-Anti-MMR Nb Accumulates in the Infarct Territory After Permanent Coronary Artery Ligation

Serial \(^{68}\)Ga-NOTA-anti-MMR Nb PET/CT images at 2, 7 and 14 days after MI were acquired in mice (Figure 3A). Elevated regional \(^{68}\)Ga-NOTA-anti-MMR Nb uptake was observed 7 days post-MI in the hypometabolic infarct territory in the myocardium as identified by \(^{18}\)FDG PET scan. The PET signal diminished by 14 days post-MI, consistent with decline of the total number of MR⁺ macrophages observed in flow cytometry analysis. However, high accumulation of the radioactivity in the abdominal area receptor-positive organs, i.e., liver and spleen (17), resulted in an intense background signal and acted as a confounder for in vivo signal quantification. Therefore, after the completion of in vivo imaging, ex vivo cardiac PET/MR scans were performed in order to confirm the cardiac origin of the in vivo signals. The ligation sites were clearly visible in T1-weighted MRI (Figure 3B). Augmented \(^{68}\)Ga-NOTA-anti-MMR Nb uptake was observed in the infarcted area, near the ligation suture (Figure 3C).

In vivo images acquired 1 h p.i. with \(^{68}\)Ga-NOTA-anti-MMR Nb for rats 7 days post-MI, are presented in Figure 4. Augmented focal signals were observed in the myocardium as seen in the coronal (Figure 4A) and axial (Figure 4B) views.
Substantial uptake was also seen in the operation scar. The PET image-derived average uptake in the myocardium was 2.1 ± 0.9%ID/g for infarct areas. The ligation sites were clearly visible in the ex vivo cardiac photographs (Figure 4C) and MRI (Figure 4D). Augmented $^{68}$Ga-NOTA-anti-MMR Nb uptake in the myocardium observed in the area close to the ligation site (Figure 4E).

$^{68}$Ga-NOTA-Anti-MMR Nb Uptake in the Infarct Region Is Specific

Ex vivo autoradiography confirmed $^{68}$Ga-NOTA-anti-MMR Nb uptake in the infarct region, as indicated by H.E. staining. To assess the specificity of $^{68}$Ga-NOTA-anti-MMR Nb accumulation and to confirm that uptake of $^{68}$Ga-NOTA-anti-MMR Nb in the injured myocardium was MR-mediated, a group of MI rats was injected with $^{68}$Ga-labeled non-targeting NOTA-BCII10 Nb 7 days after coronary ligation. Compared to targeting $^{68}$Ga-NOTA-anti-MMR Nb, non-targeting $^{68}$Ga-NOTA-BCII10 Nb uptake in the infarct region was significantly lower (Figure 5A). PET image-derived infarct-to-remote myocardium ratio was 1.8 ± 0.6 for $^{68}$Ga-NOTA-anti-MMR Nb and 0.9 ± 0.2 for $^{68}$Ga-NOTA-BCII10 Nb ($P = 0.02$) (Figure 5B). Autoradiography image-derived infarct-to-remote signal intensity ratios were 3.7 ± 1.2 and 1.5 ± 0.4 for $^{68}$Ga-NOTA-anti-MMR Nb and $^{68}$Ga-NOTA-BCII10 Nb, respectively ($P = 0.01$) (Figure 5C). $^{68}$Ga-NOTA-anti-MMR Nb showed significant uptake within the surgical wound, which was absent for the control Nb.

Molecular specificity of $^{68}$Ga-NOTA-anti-MMR Nb for the detection of MR$^+$ macrophage burden was also confirmed by the significantly decreased uptake in the infarct regions of the myocardium of MR-knockout mice (Figure 6A). Compared to wildtype mice, where MR is expressed on tissue macrophages, MR-knockout mice showed significantly lower uptake values in the infarcts. Compared to wildtype mice, the MR-knockout mice also showed lower uptake in healthy non-infarcted myocardium, confirming the lack of MR expression in extravascular cardiac tissue resident macrophages, which are known to be mainly anti-inflammatory (18). The infarct-to-remote signal intensity ratios were 4.8 ± 0.6 and 2.2 ± 0.5 for hearts dissected from wildtype and MR-knockout mice, respectively ($P = 0.001$) (Figure 6B). In addition, MR-knockout mice showed dramatically lower uptake in receptor-positive abdominal organs, confirming the absence of MR expression. Wildtype-to-knockout uptake ratios were 7.1 ± 0.2 and 15 ± 1 for liver and spleen, respectively ($P < 0.01$ for both).

Co-expression of Mannose Receptor With CD68 in the Injured Myocardium Was Confirmed by Immunofluorescence Staining

At 7 days post-MI, the radiotracer signal corresponded to increased MR$^+$ macrophages in the damaged region.
A portion of CD68-positive (CD68$^+$) macrophages located in the infarct lesions was MR$^+$ as confirmed by immunofluorescence staining (Figure 7).

DISCUSSION

This study introduces $^{68}$Ga-NOTA-anti-MMR Nb PET as novel method for molecular imaging of anti-inflammatory macrophages after MI. The time course of the $^{68}$Ga-NOTA-anti-MMR Nb PET signal closely matches the time course of reparative phase of myocardial healing, in which MR$^+$ M2 macrophages are mainly involved. $^{68}$Ga-NOTA-anti-MMR Nb uptake specifically indicates elevated expression of MR in the infarcted myocardial region. The uptake of $^{68}$Ga-NOTA-anti-MMR Nb in the infarcts of MR-knockout mice and the uptake of non-targeting $^{68}$Ga-NOTA-BCII10 Nb in the infarcts of rats were negligible, confirming the specific binding of $^{68}$Ga-NOTA-anti-MMR Nb to MR.

In the steady state of healthy myocardium, extravascular macrophages are abundant in the heart. They are mainly derived from local progenitors and are located in direct contact with myocytes and endothelial cells (18). The resident cardiac tissue macrophages (cTMs) are reported to be mainly anti-inflammatory in the steady state (18). A gene expression profiling study revealed that cTMs in murine heart express a set of 21 genes associated with alternatively activated M2 macrophages including MR (18). This explains well the high level of MR expression in macrophages isolated from steady state hearts in our flow cytometry analysis, as well as modest radiotracer uptake in healthy myocardium in ex vivo autoradiography studies. In the setting of cardiac tissue injury, however, cTMs disappear from the ischemic area (19–21). In the inflammatory phase that follows MI high numbers of inflammatory monocytes [Ly6C$^{high}$ in mice, CD14$^+$CD16$^-$ in humans (22)] invade the ischemic heart, differentiate into inflammatory macrophages, which then clear the area from dead cells and debris and fuel inflammation by releasing proteases, pro-inflammatory cytokines/chemokines, and reactive oxygen species (9). A study investigating the spatiotemporal pattern of monocyte accumulation in the human myocardium post-MI revealed that the inflammatory monocytes/macrophages initially accumulate in the infarct border zone adjacent and adherent to cardiomyocytes (23). This is most probably because the vascular system is still intact in the myocardium adjacent to the ischemic tissue. However, over time, they migrate into the infarct core. In the subsequent reparative phase, the inflammatory macrophages undergo phenotypic alterations, become reparative

FIGURE 5 | Binding specificity test in rats. (A) In vivo (PET/CT) and ex vivo (autoradiography) evaluation of targeting $^{68}$Ga-NOTA-anti-MMR Nb and non-targeting $^{68}$Ga-NOTA-BCII10 Nb biodistribution in infarcted (7 days after coronary ligation) and non-infarcted (sham-operated) rat hearts and corresponding H.E. staining. (B) PET image-derived and (C) autoradiography image-derived infarct-to-remote area uptake ratios derived from $n$ = 4 MI rats injected with $^{68}$Ga-NOTA-anti-MMR Nb and $n$ = 4 MI rats injected with $^{68}$Ga-NOTA-BCII10 Nb. QL = quantum level.
macrophages, and exert pro-fibrotic functions by promoting collagen production and neovascularization. In that setting, MR was identified to be a surface marker that is absent on inflammatory macrophages, but abundantly present on a subset of reparative macrophages (10), and hence allows the phenotype of macrophages (inflammatory vs. reparative) to be determined. We first assessed the ratio of inflammatory to reparative macrophages during the course of MI and found that macrophages indeed expressed fewer MR during the inflammatory phase after MI (day 2), while the number of MR$^+$ macrophages rose during the reparative phase (day 7). Seven days post-MI was selected as an optimal time point for the in vivo as well as ex vivo imaging studies, when the highest number of MR$^+$ cardiac macrophages were observed by flow cytometry analysis.

Selective and receptor-mediated binding of $^{68}$Ga-NOTA-anti-MMR Nb to cultured M2 macrophages was reported earlier (14). Compared to M1 macrophages,
68Ga-NOTA-anti-MMR Nb uptake was distinctly greater in IL-4-activated M2-polarized (M2a) macrophages. Incubation with excess unlabelled NOTA-anti-MMR Nb reduced radiotracer retention in M2a macrophages to the level of uptake in M1 macrophages, supporting specificity. The peak activity at day 7 post-MI is consistent with the presence of anti-inflammatory macrophages. The absence of the signal by day 3 post-MI confirms the selectivity of 68Ga-NOTA-anti-MMR Nb to late-stagebreak anti-inflammatory M2 macrophages, the results which were replicated in vitro (14).

Besides 18F-FDG, several radiopharmaceuticals targeting amino acid metabolism or specific receptors expressed by diverse inflammatory cells have been utilized for non-invasive assessment of immune cell infiltration into the ischemic myocardium (24). However, the specificity for distinct inflammatory cell subpopulations is poorly defined. 68Ga-pentixafor was tested as a molecular imaging marker of chemokine receptor type 4 (CXCR4) expression for imaging inflammatory responses after MI (25). Although the time course of the in vivo signal closely matched the time course of myocardial leukocyte infiltration, the precise cell populations contributing to the PET signal were not identified. The cellular basis of tracer uptake in different inflammatory cells was identified more clearly in some other studies. 68Ga-DOTA-ECLii has been used to track the recruitment, accumulation, and resolution of chemokine CC motif receptor 2 (CCR2)-positive pro-inflammatory leukocytes in murine models (26). CCR2+ monocytes/macrophages recruited to the injured heart are known to promote collateral tissue injury through the generation of inflammatory cytokines/chemokines. The suitability of clinically approved 11C-methionine for imaging post-MI inflammation was assessed in experimental animals and humans. It was shown that, as a marker of amino acid uptake for protein synthesis uptake, 11C-methionine accumulates in proliferating infiltrating monocytes and inflammatory M1 macrophages (27). The feasibility of visualizing infiltration of MR+ macrophages in the early diagnosis and monitoring of treatment response of myocarditis with 68Ga-labeled mannosylated human serum albumin was reported earlier (28). The present study reports the potential utility of targeting MR for molecular imaging of reparative macrophages in the infarcted myocardium.

The diverse roles of different macrophage subtypes highlight the need to design more specific radiotracers for selectively targeting and clearly elucidating the specific subtypes which may greatly benefit novel therapeutic development. Potential therapeutic agents that are able to modulate macrophage polarization and shift pro-inflammatory M1-like macrophages to anti-inflammatory M2-like macrophages may be beneficial in both early infarct repair and ventricular remodeling (29–32). Therefore, M2 macrophage-targeted molecular imaging using 68Ga-NOTA-anti-MMR Nb has potential for early interrogation of efficacy of therapeutic agents. In addition, as timing is of the essence when it comes to treatment of MI patients, non-invasive depiction of the individual inflammatory phases after ischemia may better optimize timing of treatment initiation for individual patients.

**CONCLUSION**

We have established the use of MR imaging in monitoring of myocardial infarct healing and the feasibility of 68Ga-NOTA-anti-MMR Nb for that purpose. Considering the positive conclusion for immunogenicity risk profiling in the first trial (33), 68Ga-NOTA-anti-MMR Nb PET promises a significant potential for clinical translation.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Experiments were approved by the Ethical Committee for Animal Experimentation of the Vrije Universiteit Brussel and were in accordance with the German Animal Welfare Act (Regierung von Oberbayern, Munich, Germany).

**AUTHOR CONTRIBUTIONS**

ZV: design, methodology, investigation, analysis, and writing initial manuscript. MB: methodology. SM: methodology, investigation, analysis, and supervision. A-LS, NO, and GT: methodology and analysis. AH, CR, WW, GR, and MS: supervision. HS: analysis, writing, and supervision. SH: design and supervision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research leading to these results has received funding from Deutsche Forschungsgemeinschaft (DFG): VA 1183/2-1, HA 1083/15-4, and MO 3054/1-1. This work was also supported by the Research Foundation Flanders, Belgium (FWO G005815 N). HS has received funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (STRATO, grant agreement no. 759272), the “Else Kröner-Fresenius-Stiftung” (2020_EKSE.07) and the Deutsche Forschungsgemeinschaft (SA 1668/5-1 and 470462396).

**ACKNOWLEDGMENTS**

We thank Sybille Reder and Markus Mittelhäuser for technical PET/CT assistance.
REFERENCES

1. Mendis S, Psuka P, Norrving B. Global atlas on cardiovascular disease prevention and control. 1st ed. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization (2011), p. 3–18.

2. Prabhuj SD. Post-infarction ventricular remodeling: an array of molecular events. J Mol Cell Cardiol. (2005) 38:547–50. doi: 10.1016/j.yjmcc.2005.01.014

3. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. (2000) 101:2981–8. doi: 10.1161/01. cir.101.25.2981

4. Frangiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. (2012) 110:159–73. doi: 10.1161/CIRCRESAHA.111.243162

5. Nikolaos G. Frangiannis. The immune system and cardiac repair. Pharmaceut Res. (2008) 58:88–111. doi: 10.1016/j.phrs.2008.06.007

6. Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, Kzhyshkowska J, Popov SV et al. Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci. (2017) 24:13. doi: 10.1186/s12929-017-0322-3

7. Liu J, Wang H, Li J. Inflammation and inflammatory cell types in myocardial infarction and reperfusion injury: a double-edged sword. Clin Med Insights Cardiol. (2016) 10:79–84. doi: 10.4137/CMMC.S33164

8. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of innate inflammation and repair. Circulation. (2010) 121:2437–45. doi: 10.1161/CIRCULATIONAHA.109.916346

9. Sager HB, Kessler T, Schunkert H. Monocytes and macrophages in cardiac injury and repair. J Thorac Dis. (2017) 9:530–5. doi: 10.21037/jtd.2016.11.17

10. Röszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. (2015) 2015:816460. doi: 10.1155/2015/816460.

11. Mohadeh K, Schoonoooge S, Laoui D, Houbracken I, Waelput W, Breckpot K et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. (2012) 72:4165–77. doi: 10.1158/0008-5472.CAN-11-2994

12. Blykers A, Schoonoooge S, Xavier C, D’hoé K, Laoui D, D’Huyvetter M et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. (2015) 56:1265–71. doi: 10.2967/jnumed.115.156828

13. Put S, Schoonoooge S, Devoogdt N, Schurgers E, Avau M, Mitera T et al. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med. (2013) 54:807–14. doi: 10.2967/jnumed.112.111781

14. Varasteh V, Mohanta S, Li Y, Braeuer M, López Armbruster N, Nekolla SG et al. Targeting sFlmannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68Ga-NOTA-anti-MMR Nanobody. EJMMR Med. (2019) 9:5. doi: 10.1186/s13550-019-0474-0

15. Varasteh V, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. (2019) 60:1743–9. doi: 10.2967/jnumed.19.226993

16. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation. (2015) 132:1880–90. doi: 10.1161/CIRCULATIONAHA.115.016160

17. Takahashi K, Donovan MJ, Donovan H, Hwang H, Hirsch A et al. Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur Heart J. (2014) 35:376–85. doi: 10.1093/europheart/ehu778

18. Thackeray JT, Bengel FM. Molecular imaging of myocardial inflammation with positron emission tomography post-infarction: a determinant of subsequent remodeling or recovery. JACC Cardiovasc Imaging. (2018) 11:1340–55. doi: 10.1016/j.jcmg.2018.05.026

17. Thackeray JT, Derlin T, Haghiakia A, Napp LC, Wang Y, Ross TL et al. Molecular Imaging of the Chemokine Receptor CXC4R After Acute Myocardial Infarction. JACC Cardiovasc Imaging. (2015) 8:1417–26. doi: 10.1016/j.jcmg.2015.09.008

20. Heo GS, Kopecky B, Sultan D, Ou M, Feng G, Bajpai G et al. Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart. Circ Res. (2019) 124:881–90. doi: 10.1161/CIRCRESAHA.118.314030

21. Thackeray JT, Bankstahl JP, Wang Y, Wollett KC, Bengel FM. Targeting amino acid metabolism for molecular imaging of inflammation early after myocardial infarction. Theranostics. (2016) 6:1768–79. doi: 10.7150/thno.15929

22. Wang Z, Huang S, Sheng Y, Peng X, Liu H, Jin N et al. Topiramate modulates post-infarction inflammation primarily by targeting monocytes or macrophages. Cardiovasc Res. (2017) 113:475–87. doi: 10.1093/cvr/cvx027

23. Jung M, Ma Y, Iyer RP, DeLeon-Pennix KY, Yahuthchansky A, Garrett MR et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol. (2017) 112:33. doi: 10.1007/s00395-017-0622-5

24. Shintani Y, Yoshiro K, Ishida H, Saba R, Suzuki K, Shiraishi M et al. Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest. (2016) 126:2131–66. doi: 10.1172/JCI85782

25. Ma Y, Halade GV, Zhang J, Ramirez TA, Levin D, Voorhees A et al. Matrix metalloproteinase-28 depletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res. (2013) 112:675–88. doi: 10.1161/CIRCRESAHA.113.300502

26. Ackaert C, Smiejkowska N, Xavier C, Stercks YG, Denis S, Stijlenmans B et al. Immunogenic risk profile of nanobodies. Front Immunol. (2021) 12:632687. doi: 10.3389/fimmu.2021.632687

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Varasteh, Braeuer, Mohanta, Steinseik, Habenicht, Omidvari, Topping, Rischler, Weber, Sager, Raes, Hurnot and Schwaiger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.